Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$3.43 -4.5%	$5.16	$3.18 ▼ $13.53	$161.97M	N/A	395,926 shs	615,038 shs
GHRS GH Research	$13.70 +9.6%	$10.45	$6.00 ▼ $20.50	$650.35M	0.97	185,106 shs	204,300 shs
IKT Inhibikase Therapeutics	$1.95 -0.5%	$1.99	$1.12 ▼ $4.20	$144.97M	0.94	237,429 shs	96,548 shs
ORGO Organogenesis	$3.44 +13.5%	$3.81	$2.28 ▼ $6.71	$436.38M	1.63	1.15 million shs	2.25 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	-4.46%	+4.26%	-31.81%	-28.39%	+342,999,900.00%
GHRS GH Research	+9.60%	+18.51%	+31.48%	+26.62%	+13.50%
IKT Inhibikase Therapeutics	-0.51%	-4.88%	-2.50%	-11.36%	+15.38%
ORGO Organogenesis	+13.53%	+29.32%	+12.79%	-35.09%	+25.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALMS Alumis	2.4738 of 5 stars	3.6	0.0	0.0	2.8	1.7	0.6
GHRS GH Research	1.5085 of 5 stars	3.5	0.0	0.0	1.9	2.5	0.0
IKT Inhibikase Therapeutics	1.0952 of 5 stars	3.3	2.0	0.0	0.0	0.0	0.6
ORGO Organogenesis	4.395 of 5 stars	3.3	1.0	4.3	4.2	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	3.22	Buy	$24.86	624.70% Upside
GHRS GH Research	3.00	Buy	$32.00	133.58% Upside
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	233.33% Upside
ORGO Organogenesis	2.50	Moderate Buy	$5.50	59.88% Upside

Current Analyst Ratings Breakdown

Latest IKT, ORGO, GHRS, and ALMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
5/15/2025	ALMS Alumis	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $25.00
5/13/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $29.00
5/9/2025	GHRS GH Research	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
4/30/2025	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
3/28/2025	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/26/2025	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/20/2025	ALMS Alumis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/20/2025	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $15.00

(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	$17.39M	9.31	N/A	N/A	N/A	∞
GHRS GH Research	N/A	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	$260K	557.57	N/A	N/A	$1.78 per share	1.10
ORGO Organogenesis	$458.76M	0.95	$0.22 per share	15.72	$2.11 per share	1.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/18/2025 (Estimated)
GHRS GH Research	-$35.59M	-$0.79	N/A	N/A	N/A	N/A	-20.29%	-19.49%	N/A
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
ORGO Organogenesis	$4.95M	-$0.17	N/A	N/A	N/A	-1.62%	-2.69%	-1.63%	8/6/2025 (Estimated)

Latest IKT, ORGO, GHRS, and ALMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/18/2025	N/A	ALMS Alumis	-$1.47	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ALMS Alumis	-$1.47	-$1.82	-$0.35	-$1.82	N/A	N/A
5/8/2025	Q1 2025	GHRS GH Research	-$0.61	-$0.19	+$0.42	-$0.19	N/A	N/A
5/8/2025	Q1 2025	ORGO Organogenesis	$0.04	-$0.13	-$0.17	-$0.17	$90.77 million	$86.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	11.26	11.26
GHRS GH Research	N/A	15.83	15.83
IKT Inhibikase Therapeutics	N/A	0.85	0.85
ORGO Organogenesis	0.21	3.09	2.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
GHRS GH Research	56.90%
IKT Inhibikase Therapeutics	3.81%
ORGO Organogenesis	49.57%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	N/A
GHRS GH Research	41.60%
IKT Inhibikase Therapeutics	7.30%
ORGO Organogenesis	33.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	N/A	47.22 million	N/A	N/A
GHRS GH Research	10	52.03 million	30.38 million	Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
ORGO Organogenesis	950	126.85 million	79.33 million	Optionable

IKT, ORGO, GHRS, and ALMS Headlines

Recent News About These Companies

Organogenesis Holdings: ReNu And New LCD Offer A Rebound Scenario

June 9 at 6:31 PM | seekingalpha.com

Organogenesis Holdings Inc. (NASDAQ:ORGO) Insider Purchases $414,322.89 in Stock

June 9 at 4:31 AM | americanbankingnews.com

Organogenesis Holdings Inc. (NASDAQ:ORGO) Insider Purchases $26,975.78 in Stock

June 7 at 8:45 AM | insidertrades.com

Organogenesis Holdings Inc. (NASDAQ:ORGO) Insider Purchases $26,975.78 in Stock

June 6, 2025 | marketbeat.com

Organogenesis Holdings Inc. (NASDAQ:ORGO) Insider Lori Freedman Acquires 100,863 Shares

June 6, 2025 | marketbeat.com

Insider Buying: Organogenesis Holdings Inc. (NASDAQ:ORGO) Insider Buys 142,379 Shares of Stock

June 6, 2025 | marketbeat.com

Organogenesis Holdings Inc. (NASDAQ:ORGO) Stake Cut by Nuveen Asset Management LLC

June 5, 2025 | marketbeat.com

Organogenesis: Build On Weakness For Big ReNu Knee OA Payday

June 5, 2025 | seekingalpha.com

Lazard Asset Management LLC Purchases 94,514 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

May 24, 2025 | marketbeat.com

Soleus Capital Management L.P. Acquires 645,000 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

May 21, 2025 | marketbeat.com

Jacobs Levy Equity Management Inc. Sells 232,865 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

May 21, 2025 | marketbeat.com

Deutsche Bank AG Sells 2,393,857 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

May 20, 2025 | marketbeat.com

Dimensional Fund Advisors LP Increases Stock Position in Organogenesis Holdings Inc. (NASDAQ:ORGO)

May 12, 2025 | marketbeat.com

Organogenesis Holdings Inc. (ORGO) Q1 2025 Earnings Call Transcript

May 11, 2025 | seekingalpha.com

Organogenesis Holdings Inc. (NASDAQ:ORGO) Stake Trimmed by AQR Capital Management LLC

May 11, 2025 | marketbeat.com

Earnings call transcript: Organogenesis Q1 2025 sees revenue drop, stock plummets

May 11, 2025 | investing.com

Earnings call transcript: Organogenesis Q1 2025 sees revenue drop, stock plummets

May 11, 2025 | investing.com

Organogenesis Holdings First Quarter 2025 Earnings: Misses Expectations

May 10, 2025 | finance.yahoo.com

Organogenesis (ORGO) Reports Q1 Loss, Lags Revenue Estimates

May 8, 2025 | zacks.com

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

CMS reviewing coverage policies for skin substitute products

April 12, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT, ORGO, GHRS, and ALMS Company Descriptions

Alumis NASDAQ:ALMS

$3.43 -0.16 (-4.46%)

Closing price 06/9/2025 04:00 PM Eastern

Extended Trading

$3.46 +0.02 (+0.73%)

As of 06/9/2025 07:46 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

GH Research NASDAQ:GHRS

$13.70 +1.20 (+9.60%)

Closing price 06/9/2025 04:00 PM Eastern

Extended Trading

$13.78 +0.08 (+0.58%)

As of 06/9/2025 07:53 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Inhibikase Therapeutics NYSE:IKT

$1.95 -0.01 (-0.51%)

Closing price 06/9/2025 04:00 PM Eastern

Extended Trading

$1.94 -0.01 (-0.51%)

As of 06/9/2025 04:08 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Organogenesis NASDAQ:ORGO

$3.44 +0.41 (+13.53%)

Closing price 06/9/2025 04:00 PM Eastern

Extended Trading

$3.44 0.00 (0.00%)

As of 06/9/2025 07:50 PM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time